Business Wire

Alveo Technologies Announces New Executive Leadership, Open Platform Strategy


Alveo Technologies, Inc. (Alveo) today announced the appointment of three life sciences industry leaders to its senior executive team to advance the development of its novel molecular sensing and diagnostics technology and lead the company through strategic growth and commercialization of its rapid, multiplexed molecular diagnostic platform, be.well™. The company, seeking to catalyze broader adoption of its highly differentiated platform, is actively seeking collaborators to rapidly expand the menu of assays available within healthcare and beyond.

The innovative be.well™ platform, a prior X-Prize winner, pairs advanced molecular assays with secure, HIPAA- and GDPR-compliant cloud-enabled data analytics for real-time disease, pathogen and contaminant diagnoses, detection, and analysis. Designed to bring molecular sensing and diagnostics closer to the point of need, whether at the point of care, over the counter, at home, or in the field, the rapid, handheld and portable be.well™ platform can be customized to detect a wide range of diseases including COVID-19, Influenza A/B, and RSV, sexually transmitted infections and urinary tract infections as well as applications for veterinary, agricultural, and other industrial markets where low cost, accurate, rapid molecular testing, sampling, or detection capabilities are needed.

New Executive Leadership to Ensure Universal Access to Groundbreaking Technology

Shaun Holt, Chief Executive Officer, and Chairman of the Board of Directors

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

Erik Tyrrell-Knott, Chief Business and Strategy Officer

As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering, and product management efforts, driving the Company’s commercial, partnership, and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Slava Elagin, PhD, MBA, Chief Technology Officer

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industries. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.

Proprietary Advanced Molecular Sensing Technology Offers Distinct Advantages

Alveo is leading the transformation of the point-of-need molecular sensing and health tech markets with an “open platform” approach to co-developing rapid molecular testing capabilities with collaborative partners across multiple markets.

“Alveo has spent seven years and more than $70 million dollars developing a bulletproof, mobile “Molecular Lab” that can deliver exquisitely sensitive and specific testing wherever, whenever it is needed: literally in the field for crop testing, on farms for animal testing, and most importantly in labs, pharmacies, and doctors’ offices for various infectious diseases,” says CEO Shaun Holt. “The future of healthcare, and molecular sensors as a whole, lies closer and closer to the patient or point of need, and the multiplexed Alveo platform will deliver insight and guidance with zero compromise.”

The be.well™ platform is the only point-of-care diagnostic platform available today that utilizes Alveo’s proprietary and globally patented method for the direct electrical sensing of nucleic acid amplification. This technology eliminates the need for specialized lighting and expensive optical detectors, while also simplifying certain aspects of primer manufacturing, providing a more robust and reliable diagnostic instrument.

Alveo’s platform can be used with various specimen types, such as nasal, blood, or urine samples, which eliminates the need to modify the platform design for different disease applications. The design architecture -- with a total of 15 components -- is reusable and rechargeable, Bluetooth- and cloud-enabled, with no moving parts or hazardous waste, is environmentally friendly, reduces manufacturing costs and limits supply chain risk. The simplicity of the detection methodology, its lower cost compared to other single-use diagnostic tests, and its wide range of health and disease applications are key advantages driving Alveo’s commercialization partnerships.

“A seminal pillar of Alveo’s growth is to open our platform to companies with expertise, market reach, and customer insights that extend beyond what Alveo can accomplish on our own,” says Erik Tyrrell-Knott. “Collaborating with partners to take molecular testing out of the lab, into new markets, and deliver actionable insights at the point of need is our core focus. The doors are open, and we are ready to co-develop.”

Alveo’s be.well™ COVID-19 Test received CE (Conformité Européene) Mark regulatory approval and the company is initially scaling up production for commercialization in the United Kingdom and European Union. Alveo is also actively pursuing 510(K) clearance from the U.S. Food and Drug Administration.

About Alveo

At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.

To learn more, visit

To view this piece of content from, please give your consent at the top of this page.

Contact information

Staci Vernick for Alveo Technologies, Inc.
SL Vernick Communications

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carbios Hosts World’s First PET Biorecycling Summit with Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker9.12.2022 08:45:00 EET | Press release

Regulatory News: This press release features multimedia. View the full release here: Bertrand Piccard, Initiator and Chairman of the Solar Impulse Foundation, as Keynote Speaker at the First World PET Biorecycling Summit organised by Carbios Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, hosted the world’s first PET Biorecycling Summit from 7 to 8 December 2022 in Paris. The event attracted over 100 international participants from the scientific, academic, and industrial worlds to exchange on the advances in the field of biological recycling, and how to bring these innovations for a circular economy to market. The two-day conference gathered world-renowned scientists from various academic institutions to share their latest research on PET enzymatic depolymerization. Bertrand Piccard, Initiator and Chairman

Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble™9.12.2022 06:30:00 EET | Press release

Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble ™ is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumble will release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble , fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer a

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 02:00:00 EET | Press release

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the

TreviPay Acquires Apruve9.12.2022 01:45:00 EET | Press release

TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy9.12.2022 00:05:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom